Follow us on Twitter
twitter icon@FreshPatents


Anxiety patents

      

This page is updated frequently with new Anxiety-related patent applications.




 Magnesium compositions and uses thereof for neurological disorders patent thumbnailMagnesium compositions and uses thereof for neurological disorders
A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound.
Neurocentria, Inc.


 Indolin-2-one or pyrrolo-pyridin-2-one derivatives patent thumbnailIndolin-2-one or pyrrolo-pyridin-2-one derivatives
The compounds may be used in the treatment of cns diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, alzheimer's disease, autism, parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, huntington's disease, adhd, amyotrophic lateral sclerosis, epilepsy, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems.. .

 Methods of diagnosing and treating anxiety disorder patent thumbnailMethods of diagnosing and treating anxiety disorder
Methods and uses for diagnosing and treating anxiety disorders are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mglur) network genes and wherein treatment is with nonspecific activators of mglurs such as fasoracetam.. .
The Children's Hospital Of Philadelphia


 Peptides as oxytocin agonists patent thumbnailPeptides as oxytocin agonists
The present compounds compounds are oxytocin receptor agonists for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of prader-willi syndrome.. .
Hoffmann-la Roche Inc.


 Peptides as oxytocin agonists patent thumbnailPeptides as oxytocin agonists
The present compounds are oxytocin receptor agonists for the treatment of autism, stress, including post-traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of prader-willi syndrome.. .
Hoffmann-la Roche Inc.


 Heteroaromatic compounds and their use as dopamine d1 ligands patent thumbnailHeteroaromatic compounds and their use as dopamine d1 ligands
And pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating d1-mediated (or d1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, ad, pd, or pharmacotherapy therapy), adhd, impulsivity, compulsive gambling, overeating, autism spectrum disorder, mcl, age-related cognitive decline, dementia, rls, parkinson's disease, huntington's chorea, anxiety, depression, mdd, trd, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, sle, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.. .

 (2r)-2-propyloctanoic acid for functional brain disease patent thumbnail(2r)-2-propyloctanoic acid for functional brain disease
An agent for preventing or treating a functional brain disease and/or inhibiting symptom development of the functional brain disease includes (2r)-2-propyloctanoic acid or a salt thereof. The agent may be safely administered to patients of, for example, functional brain diseases such as depression, menopausal mood disorder, perimenopausal mood disorder, panic disorder, irritable bowel syndrome, social anxiety disorder, post-traumatic stress disorder or the like, and also can show excellent effects..
Ono Pharmaceutical Co., Ltd.


 Derivatives of rufinamide and their use in inhibtion of the activation of human voltage-gated sodium channels patent thumbnailDerivatives of rufinamide and their use in inhibtion of the activation of human voltage-gated sodium channels
The present invention provides compounds of formula i which are capable of inhibition of the activation of hnav1.1 or hnav1.6 sodium channels in neurons. Pharmaceutical compositions comprising these compounds are also provided.
The Johns Hopkins University


 Methods for the treatment of depression and anxiety patent thumbnailMethods for the treatment of depression and anxiety
Methods of treating a depressive disorder or an anxiety disorder in a subject in need of such treatment are described. A therapeutically effective amount of a composition comprising ac-nle4-c[asp5-his6-(nme)d-nal(2′)7-arg8-trp9-(nme)lys10]-nh2 (peptide 9), in a pharmaceutically acceptable carrier is administered to the subject.
The Arizona Board Of Regents On Behalf Of The University Of Arizona


 Treatment of social anxiety disorder, obsessive compulsive disorder and panic disorder using botulinum toxin patent thumbnailTreatment of social anxiety disorder, obsessive compulsive disorder and panic disorder using botulinum toxin
Methods are disclosed for treating social anxiety disorder, obsessive compulsive disorder, and/or panic disorder in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilli and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilli and/or a procerus muscle in the subject, thereby treating ptsd.

Inhibitors of the fkbp51 protein from a high-throughput drug screen and methods of use

The subject invention concerns materials and methods for treating depression, stress disorders, such as ptsd, anxiety disorders, and/or a neurodegenerative disease or condition in a person or animal. In one embodiment, a person or animal in need of treatment is administered one or more compounds or drugs, or a composition comprising the one or more compounds or drugs, that inhibit fkbp51 activity or function.
University Of South Florida

Long range portable pet or owner initiated two way audio-video communication device

A portable device and a method for a domestic pet to contact its master whenever the pet desires so is disclosed. The device comprises of two units and an interconnecting mechanism between them via wireless communication methods such as bluetooth© or other equivalent rf technologies.

Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.. .
Auspex Pharmaceuticals, Inc.

1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto

The present invention relates to compounds of formula (ia) and pharmaceutical compositions thereof that modulate the activity of gpr52. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a gpr52-mediated disorder (e.g., huntington's disease, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder (adhd), or tourette's syndrome); an extrapyramidal or movement disorder; a motor disorder; a hyperkinetic movement disorder; a psychotic disorder; catatonia; a mood disorder; a depressive disorder; an anxiety disorder; obsessive-compulsive disorder (ocd); an autism spectrum disorder; a prolactin-related disorder (e.g., hyperprolactinemia); a neurocognitive disorder; a trauma- or stressor-related disorder (e.g., posttraumatic stress disorder (ptsd)); a disruptive, impulse-control, or conduct disorder; a sleep-wake disorder; a substance-related disorder; an addictive disorder; a behavioral disorder; hypofrontality; an abnormality in the tuberoinfundibular, mesolimbic, mesocortical, or nigrostriatal pathway; decreased activity in the striatum; cortical dysfunction; neurocognitive dysfunction; and conditions related thereto.
Arena Pharmaceuticals, Inc.

Heterocyclic compounds for the treatment of neurological and psychological disorders

Lactam compounds of formula i and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.. .
Alkermes Pharma Ireland Limited

Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.. .
Auspex Pharmaceuticals, Inc.

Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders

The present invention provides peptides for use in a medicament which is administered nasally, wherein the peptide is an agonist of neuropeptide s receptor (npsr), of the receptor tgr23 and/or of vasopressin receptor-related receptor 1 (vrr1) or for use in the treatment of a patient by causing, promoting or increasing relieve or healing of phobic anxiety, avoidance anxiety, dis-sociative anxiety such as flashbacks, depersonalisation, derealisation, intrusions, vegetative symptoms related to anxiety symptoms, especially in panic attacks, in posttraumatic stress disorder, in generalised anxiety disorder and in anxiety accompanying depressive, or psychotic episodes, arousal, awakening, alertness, activity, spontaneous movement, an anxiolytic effect or a combination thereof in the patient, wherein the peptide is administered nasally or for use in the prophylaxis and/or treatment of an anxiety or sleep dis-order, especially in any type of hypersomnia like idiopathic hypersomnia, wherein the peptide is administered nasally. Further provided are pharmaceutical compositions for nasal administration comprising at least one of said peptides, uses of said peptide or said pharmaceutical composition.
Max-planck-gesellschaft Zur Forderung Der Wissenschaft E.v.

Compressed tablet containing cannabidiol, its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders

The present invention relates to compressed tablets for peroral delivery of the cannabinoid cannabidiol (cbd). More particularly, the invention provides a compressed tablet having a tablet weight of 60-1200 mg, said tablet being composed of: 50-95 wt.
Echo Pharmaceuticals B.v.

Pyrazine derivatives

Or to a pharmaceutically suitable acid addition salt thereof, to all racemic mixtures, all their corresponding enantiomers and/or optical isomers, which may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (adhd), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, parkinson's disease, neurodegenerative disorders, alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.. .

Substituted benzamides

Compounds of formula i have a good affinity to the trace amine associated receptors (taars), especially for taar1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (adhd), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as parkinson's disease, neurodegenerative disorders such as alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders..

Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders

Personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, parkinson's disease, dementia, alzheimer's disease, cognitive impairment, chemotherapy-induced cognitive dysfunction (“chemobrain”), down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs, selected from alcohol, opiates, methamphetamine, phencyclidine and cocaine.. .

Protective shield for an animal

A novel protective shield to prevent an animal from licking or biting at wounds or stitches is disclosed. Unlike the common elizabethan collar, the disclosed shield is open at the top to reduce stress and anxiety which may be caused by elizabethan collars.

Humanized anti-acth antibodies and use thereof

The present invention is directed to antibodies and fragments thereof having binding specificity for acth. Embodiments of this invention relate to the binding fragments of antibodies described herein, comprising the sequences of the vh, vl and/or cdr polypeptides described herein, and the polynucleotides encoding them.
Alder Biopharmaceuticals, Inc.

An amorphous vortioxetine and salts thereof

The present invention relates to an amorphous vortioxetine and salts thereof. In particular, the invention relates to a process for the preparation of an amorphous vortioxetine hydrobromide.
Cadila Healthcare Limited

Pharmaceutical composition for treating or preventing neuropsychiatric disease, containing flavone-6-c-glucose derivatives as active ingredients

The present invention provides a pharmaceutical composition or a food composition comprising, as active ingredients, flavone-6-c-glucose derivatives or galenical extracts containing flavone-6-c-glucose derivatives. The composition of the present invention shows a functional effect of effectively treating or preventing cognitive dysfunction disorders such as delirium, dementia or amnesia, stroke, palsy, attention disorders, anxiety disorders or sleep disorders..
Dae Hwa Pharma. Co., Ltd.





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Anxiety for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Anxiety with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.1987

file did exist - 2738

0 - 1 - 51